Ascentage Pharma Group International
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Dajun Yang
- Full Time Employees
- 567
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Suzhou Industrial Park Suzhou People's Republic of China 215000
- IPO Date
- May 21, 2021
- Website
- ascentagepharma.com
- Similar Companies
- Business
- Ascentage Pharma Group International is a global, integrated biopharmaceutical company specializing in the discovery, development, and commercialization of innovative therapies primarily targeting hematological malignancies and other cancers. The company’s core products include Olverembatinib, a novel third-generation BCR-ABL1 tyrosine kinase inhibitor approved in China for chronic myeloid leukemia with T315I mutations and resistant or intolerant to earlier generation TKIs; Lisaftoclax (APG-2575), a novel, oral Bcl-2 inhibitor approved in China for chronic lymphocytic leukemia/small lymphocytic lymphoma patients who have undergone prior systemic therapies including BTK inhibitors; and a pipeline featuring small molecule candidates such as APG-1387 (apoptosis protein inhibitor for solid tumors and chronic hepatitis B), APG-2449 (oral kinase inhibitor), and APG-5918 (embryonic ectoderm development inhibitor). Ascentage also focuses on drug candidates targeting apoptotic pathways, IAP, MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors, actively progressing nine global clinical trials, including registrational Phase III studies. Founded in 2009 and headquartered in Suzhou, China, Ascentage Pharma operates commercially in China and globally through clinical trials and partnerships, with key collaborations involving major pharmaceutical and biotechnology companies such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, as well as academic institutions including Dana-Farber Cancer Institute, Mayo Clinic, MD Anderson Cancer Center, and the University of Michigan. The company is publicly listed on the Hong Kong Stock Exchange (ticker 6855.HK) and the NASDAQ (ticker AAPG) since January 2025. Recent major developments include the 2024 closing of a $75 million strategic equity investment by Takeda; the official approval and commercialization of Lisaftoclax in China for CLL/SLL treatment, with ongoing global Phase III trials such as the FDA-cleared GLORA-4 study exploring lisaftoclax combined with azacitidine for higher-risk myelodysplastic syndromes; a 93% year-over-year increase in sales of Olverembatinib in the first half of 2025; and expanded commercial reach with over 780 pharmacies and hospitals distributing Olverembatinib. The company is actively presenting multiple clinical data sets at major scientific conferences, highlighting promising efficacy results in various hematologic malignancies, and is focused on advancing clinical development with the goal of addressing unmet medical needs in cancer and related diseases.
Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call Transcript
Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Ascentage Pharma Group International (OTCMKTS:ASPHF) Sees Significant Increase in Short Interest
Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ascentage Pharma Group International (OTCMKTS:ASPHF) Stock Price Down 23.4% – Should You Sell?
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update
Ascentage Pharma Group International (AAPG) Presents At Citi's Biopharma Back To School Conference Transcript
Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO
Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO
Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA
ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation
ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress
Ascentage Pharma Announces 2024 Interim Results